- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04391049
Prueba de la adición de la terapia viral anticancerosa Telomelysin™ a la quimiorradiación para pacientes con cáncer de esófago avanzado que no son candidatos para la cirugía
Ensayo de fase I con cohorte de expansión de OBP-301 (Telomelysin™) y quimiorradiación definitiva para pacientes con cáncer de esófago y gastroesofágico localmente avanzado que no son candidatos para cirugía
This phase I trial studies the side effects of OBP-301 when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with esophageal or gastroesophageal cancer that invades local or regional structures. OBP-301 is a virus that has been designed to infect and destroy tumor cells (although there is a small risk that it can also infect normal cells). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving OBP-301 with chemotherapy and radiation therapy may work better than standard chemotherapy and radiation therapy in treating patients with esophageal or gastroesophageal cancer.
Descripción general del estudio
Estado
Condiciones
- Adenocarcinoma de la unión gastroesofágica en estadio clínico III AJCC v8
- Adenocarcinoma irresecable de la unión gastroesofágica
- Terapia posneoadyuvante Adenocarcinoma de la unión gastroesofágica en estadio III AJCC v8
- Terapia posneoadyuvante Adenocarcinoma de la unión gastroesofágica en estadio IIIA AJCC v8
- Terapia posneoadyuvante Adenocarcinoma de la unión gastroesofágica en estadio IIIB AJCC v8
- Adenocarcinoma de esófago en estadio clínico II AJCC v8
- Adenocarcinoma de esófago en estadio clínico IIA AJCC v8
- Adenocarcinoma de esófago en estadio clínico III AJCC v8
- Adenocarcinoma de esófago en estadio patológico II AJCC v8
- Adenocarcinoma de esófago en estadio patológico IIA AJCC v8
- Adenocarcinoma de esófago en estadio patológico IIB AJCC v8
- Adenocarcinoma de esófago en estadio patológico III AJCC v8
- Adenocarcinoma de esófago en estadio patológico IIIA AJCC v8
- Adenocarcinoma de esófago en estadio patológico IIIB AJCC v8
- Carcinoma de células escamosas
- Adenocarcinoma de la unión gastroesofágica en estadio clínico II AJCC v8
- Adenocarcinoma de esófago en estadio clínico IIB AJCC v8
- Adenocarcinoma avanzado de la unión gastroesofágica
- Cáncer de células escamosas
- Adenocarcinoma de la unión gastroesofágica en estadio patológico III AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio patológico IIIA AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio patológico IIIB AJCC v8
- Terapia posneoadyuvante Adenocarcinoma de esófago en estadio III AJCC v8
- Terapia posneoadyuvante Adenocarcinoma de esófago en estadio IIIA AJCC v8
- Terapia posneoadyuvante Adenocarcinoma de esófago en estadio IIIB AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio clínico IIA AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio clínico IIB AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio patológico II AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio patológico IIA AJCC v8
- Adenocarcinoma de la unión gastroesofágica en estadio patológico IIB AJCC v8
- Adenocarcinoma esofágico avanzado
- Terapia posneoadyuvante Adenocarcinoma de esófago en estadio II AJCC v8
- Terapia posneoadyuvante Adenocarcinoma de la unión gastroesofágica en estadio II AJCC v8
Intervención / Tratamiento
Descripción detallada
PRIMARY OBJECTIVE:
I. To determine if the addition of OBP-301 to chemoradiation with carboplatin/paclitaxel is safe.
SECONDARY OBJECTIVES:
I. To assess toxicities associated with the addition of OBP-301 to chemoradiation.
II. To assess the number of clinical complete responses (cCR).
III. To assess the number of patients alive/without progression (progression-free survival [PFS]) and the number of patients alive (overall survival [OS]) at 1 and 2 years.
EXPLORATORY OBJECTIVE:
I. To report correlate outcomes - cCR, PFS and OS - with immune and virus-based correlative assays.
OUTLINE:
This study will evaluate an initial dose of OBP-301 and a de-escalated dose, if needed.
Patients receive OBP-301 by intratumoral injection via endoscopy on days -3, 12, and 26. Patients also receive carboplatin intravenously (IV) over 30 minutes and paclitaxel IV over 60 minutes on days 1, 8, 15, 22, and 29, and undergo radiation therapy on Monday through Friday beginning day 1 for 28 fractions over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 and 6-8 weeks, then every 3 months for 2 years.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope Comprehensive Cancer Center
-
South Pasadena, California, Estados Unidos, 91030
- City of Hope South Pasadena
-
Upland, California, Estados Unidos, 91786
- City of Hope Upland
-
-
Florida
-
Tampa, Florida, Estados Unidos, 33612
- Moffitt Cancer Center
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Cancer Center
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Memorial Sloan Kettering Basking Ridge
-
Middletown, New Jersey, Estados Unidos, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Estados Unidos, 07645
- Memorial Sloan Kettering Bergen
-
-
New York
-
Commack, New York, Estados Unidos, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Estados Unidos, 10604
- Memorial Sloan Kettering Westchester
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
Uniondale, New York, Estados Unidos, 11553
- Memorial Sloan Kettering Nassau
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- UT MD Anderson Cancer Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma or squamous cell carcinoma (SCC) of the esophagus or gastroesophageal junction (GEJ) within 90 days prior to registration
- Gastroesophageal junction tumors must be Siewert type I/II
-
Required diagnostic workup for study entry:
- History/physical examination prior to registration
- Computed tomography (CT) of the chest/abdomen with intravenous contrast within 28 days prior to registration; If CT contrast is contraindicated magnetic resonance imaging (MRI) of the chest/abdomen without contrast is permitted
- Bronchoscopy for squamous cell carcinoma (SCC) tumors that are adjacent to the airway to exclude a tracheoesophageal fistula within 42 days prior to registration
- Endoscopic ultrasound (if technically feasible) within 90 days prior to registration
- Whole body positron emission tomography (PET)/CT scan within 42 days prior to registration: Note: scan will be used for radiation treatment planning, in addition to ruling out metastatic disease
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 within 14 days prior to registration
-
Adequate hematologic function within 14 days prior to registration defined as follows Absolute neutrophil count ≥ 1,500/mcL (within 14 days prior to registration) Hemoglobin ≥ 9 gm/dL (within 14 days prior to registration) Platelets ≥ 100,000/mcL (within 14 days prior to registration)
-
Adequate renal function within 14 days prior to registration defined as follows Creatinine clearance of ≥ 50 ml/min (as calculated by Cockcroft-Gault equation) (within 14 days prior to registration)
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (within 14 days prior to registration)
-
AST/ALT ≤ 2.5 x ULN
-
Patients for whom non-operative management is a viable option in the opinion of a thoracic surgeon and/or multidisciplinary team and are candidates for chemoradiation; this does not preclude patients from receiving surgery after chemoradiation if felt to me medically indicated;
-
Patients must, in the opinion of a treating gastroenterologist, have a tumor that is amenable to intratumoral injection with at least 1 mL (1 x 10^12 vp/mL) of OBP-301 and be a candidate for 3 endoscopy procedures
-
Female patients of child bearing potential must have a negative serum/urine pregnancy test within 14 days prior to study entry. A female not of childbearing potential is one who has undergone a hysterectomy, bilateral oophorectomy, tubal ligation, or who has had no menses for 12 consecutive months
-
Patients of reproductive potential must agree to use effective contraception for the duration of study treatment as well as 6 months (for women) or 12 months (for men) after the last administered injection of OBP-301. Effective contraception includes oral contraceptives, implantable hormonal contraception, double-barrier method or intrauterine device
-
The patient must provide study-specific informed consent prior to study entry
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Known acute or chronic hepatitis B or C infection (testing not required prior to study entry in patients with no known history of hepatitis B or C)
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- For patients with a history of hepatitis C virus (HCV) infection, they must (i) have been treated and cured, (ii) for patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to study entry are eligible for this trial
Exclusion Criteria:
-
Definitive clinical or radiologic evidence of metastatic disease including:
- Positive malignant cytology of the pleura, pericardium or peritoneum
- Radiographic evidence of involvement of any adjacent mediastinal structure, e.g. aorta, trachea, which would increase the risk of repeated endoscopic interventions
- Tracheoesophageal fistula
- Radiographic evidence of distant organ involvement
- Non-regional lymph nodes that cannot be contained within a radiation field
-
More than 1 esophageal lesion
-
Prior systemic chemotherapy for the study cancer
-
Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
-
Biopsy-proven tumor invasion of the tracheobronchial tree or presence of tracheoesophageal fistula or recurrent laryngeal or phrenic nerve paralysis
-
For patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, a New York Heart Association functional classification 2C or worse
-
Uncontrolled diabetes
-
Infection requiring IV antibiotics at the time of registration
-
Patients requiring immunosuppressive medications including chronic suppressive steroid therapy (greater than the equivalent of 20 mg/day of prednisone), methotrexate, azathioprine and TNF-alpha blockers within 7 days prior to study entry
-
Received live vaccine within 30 days prior to registration
-
Received a blood transfusion, hematopoietic agent; granulocyte-colony stimulating factor (G-CSF), and/or oxygen supplementation within 7 days before the screening lab
-
Breast feeding females
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Treatment (OBP-301, carboplatin, paclitaxel, radiation)
Patients receive OBP-301 (1×10^12 vp/mL) by intra-tumoral injection via endoscopy on days -3, 12, and 26. Patients also receive paclitaxel IV (50 mg/m^2) over 60 minutes followed by carboplatin IV (AUC 2) over 30 minutes and on days 1, 8, 15, 22, and 29, and undergo radiation therapy (1.8 Gy/faction) on Monday through Friday beginning day 1 for 28 fractions (50.4 Gy total) over 5.5 weeks. All treatment continues in the absence of disease progression or unacceptable toxicity. |
Intravenously (IV)
Otros nombres:
Intravenously (IV)
Otros nombres:
Daily fractions
Otros nombres:
Intra-tumoral injection
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants Experiencing Any Dose-Limiting Toxicities (DLTs)
Periodo de tiempo: From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Adverse events are graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, which grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. A DLT is defined as the following that are definitely or probably attributed to OBP-301:
If 0 or 1 participants of 6 participants experienced a DLT, then the treatment regimen would be considered safe (and 9 more would be accrued for secondary endpoints). Otherwise, the regimen would be deemed too toxic and a second cohort of six participants would be accrued to a lower dose of OBP-301 (1 x 10^11 vp/mL). |
From start of protocol treatment until 30 days after the completion of chemoradiation, approximately 10 weeks.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Número de participantes vivos a los 1 y 2 años
Periodo de tiempo: A los 1 y 2 años
|
A los 1 y 2 años
|
|
|
Number of Participants by Highest Grade Adverse Event Reported
Periodo de tiempo: From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grades adverse event severity as follows: 1 = mild, 2 = moderate, 3 = severe, 4 = life-threatening, 5 = death related to adverse event. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. |
From start of protocol treatment to last follow-up. Maximum follow-up was 28.7 months.
|
|
Number of Participants With Clinical Complete Response (cCR)
Periodo de tiempo: 6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
Clinical complete response is defined as grossly free of disease as determined by a visual inspection or if the visual inspection was not certain, then a negative biopsy. The number of participants is determined for two populations:
|
6-8 weeks after completion of chemoradiation, approximately 11.5-13.5 weeks from baseline.
|
|
Number of Participants Alive Without Progression at 1 and 2 Years
Periodo de tiempo: At 1 and 2 years
|
Progression is defined as pathologically confirmed recurrence of local disease or clinical evidence of distant disease. |
At 1 and 2 years
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Geoffrey Y Ku, NRG Oncology
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Neoplasias
- Neoplasias por tipo histológico
- Neoplasias Glandulares y Epiteliales
- Carcinoma
- Carcinoma De Células Escamosas
- Neoplasias De Células Escamosas
- Químicos orgánicos
- Terapéutica
- Hidrocarburos
- Cicloparafinas
- Hidrocarburos, alicíclicos
- Hidrocarburos, cíclico
- Terpenos
- Fenómeno físico
- Complejos de coordinación
- Taxaides
- Ciclodecanos
- Diterpenos
- Economía y organizaciones de la atención médica
- Ciencias económicas
- Carboplatino
- Paclitaxel
- Radioterapia
- Radiación
- Impuestos
Otros números de identificación del estudio
- NRG-GI007
- U10CA180868 (Subvención/contrato del NIH de EE. UU.)
- NRG-GI007 (Otro identificador: CTEP)
- NCI-2020-02320 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- NRG-GI007 (Otro identificador: NRG Oncology)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .